PhaseBio Pharmaceuticals, Inc. (PHAS) Stock: Is This Biotechnology Stock Worth Your Attention?

0

PhaseBio Pharmaceuticals, Inc. (PHAS) is trending up in the market in today’s trading session. The company, one that is focused on the biotechnology industry, is currently priced at $6.75 after climbing 8.17% so far in today’s session. When it comes to biotechnology stocks, there are quite a few factors that have the potential to cause gains in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines relating to PHAS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 11:57AM PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
08:00AM PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019
Mar-18-19 07:29AM PhaseBio’s stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent
Mar-17-19 03:00PM Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiologys 68th Annual Scientific Session
Mar-06-19 08:00AM PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference

However, any time investors are making an investing decision, prospective investors should look into much more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s happening in regard to PhaseBio Pharmaceuticals, Inc..

Recent Moves From PHAS

While a move up on a single session, like what we’re seeing from PhaseBio Pharmaceuticals, Inc. might lead to excitement in some investors, that by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always important to take a look at trends further out than a single session. As it relates to PHAS, here are the trends that we’ve seen:

  • Past 5 Trading Sessions – In the past 5 trading sessions, PHAS has produced a change in value that amounts to 81.45%.
  • Past Month – The monthly returns from PhaseBio Pharmaceuticals, Inc. has been 125.15%.
  • Past 3 Months – Throughout the past three months, the stock has generated a return on investment that works out to 95.09%
  • Past 6 Months – Throughout the past 6 months, we have seen a change of 0 from the stock.
  • Year To Date – Since the open of this year PHAS has generated a return on investment of 118.45%.
  • Full Year – Finally, throughout the past full year, we have seen a change amounting to 0 out of PHAS. In this period, the stock has sold at a high price of -23.99% and a low of 164.71%.

Important Ratios

Looking at a few key ratios having to do with a stock can give prospective traders an understanding of just how dangerous and/or potentially profitable a pick might be. Below are some of the key ratios to think about when digging into PHAS.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. As the short ratio heads up, it shows that more investors have a belief that the stock is going to fall. In general, biotechnology stocks tend to have a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, when it comes to PhaseBio Pharmaceuticals, Inc., the stock’s short ratio comes to 0.07.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to pay for its debts when they mature with only current assets or quick assets. Because many biotech companies are heavily reliant on continued support from investors, the current and quick ratios can look upsetting. However, several better companies in the biotechnology sector come with good current and quick ratios. When it comes to PHAS, the quick and current ratios add up to 3.20 and 3.20 respectively.  

Book To Share Value – The book to share value compares the current book value of assets owned by the company to the share price of the stock. In this particular case, that ratio equates to -151.73.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotech sector, this is an important ratio to consider. In terms of PHAS, the cash to share value ratio works out to 1.07.

How Analysts Feel About PhaseBio Pharmaceuticals, Inc.

Although it’s not a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their opinions to validate your own thoughts before making investment decisions in the biotech industry. Here are the most recent moves that we’ve seen from analysts when it comes to PHAS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-13-18 Initiated Needham Buy $18
Nov-12-18 Initiated Stifel Buy $14
Nov-12-18 Initiated Citigroup Buy $18

Is Big Money Interested In PhaseBio Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PHAS, here’s what we’re seeing:

  • Institutional Investors – Currently, institutions hold 64.90% of PHAS. Nonetheless, it is important to note that institutional ownership has moved in the amount of 0 in the past 3 months.
  • Investors On The Inside – as it relates to insiders, insiders of the company currently own 0.10% of PhaseBio Pharmaceuticals, Inc.. Their ownership of the company has changed in the amount of 0 over the last 3 months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 22.65M shares of PhaseBio Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PHAS has a float of 20.49M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PHAS, the short percent of the float is 0.06%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.25. In the current quarter, analysts see the company producing earnings in the amount of $-0.31. Over the last 5 years, PHAS has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -22.60% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I am highly dependent on humans. You may not consider this when reading my articles, but it was a human! Even though my builder enabled me to learn by myself, it is much easier to do so with the help of feedback from humans. At the bottom of this article, you’ll find a section for comments. If you’d like for me find other information, update the way I communicate, comprehend something from an alternative angle, or you’re interested in teaching me anything else, I want to hear from you. If you’ve got something to offer leave a comment below. I will read that comment and it will help me become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here